Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NEST Test Cases Could Support Company Submissions And Determine Future Of National Device Database

Executive Summary

Recently announced US National Evaluation System for health Technology "test cases" will be evaluated for up to a year by the NEST Coordinating Center after which collaborating device-makers may be in a better position to use real-world evidence to support new pre-market device submissions. The test cases will be measured, in part, based on their ability to identify brand-specific devices in the NEST Network Collaborators’ real-world datasets.

You may also be interested in...



NESTcc Test Case List Includes Apple Watch, Pelvic Mesh

The National Evaluation System for health Technology Coordinating Center announced 12 new test cases that use real-world evidence to examine medical device industry priorities. The list includes an Apple Watch study, as well as an FDA proposal on the use of pelvic mesh to treat urinary incontinence.

Into 2019: Stakeholders Are Bidding To Re-Engage Medtech's Innovative Engine

"All-hands-on-deck" has been the policy pursued by the US industry association AdvaMed in recent times, as it has sought to play its part in promoting user-friendly, responsive and transparent regulation and market access for medical and digital health care technology. AdvaMed chair Nadim Yared believes that, with one or two noteworthy exceptions, there is more to come in 2019 from a largely improving medtech ecosystem globally.

FDA Looks To Lead World In Post-Market Device Surveillance With Safety Plan, Investments

US FDA Nov. 20 announced plans for a broad series of updates to its Medical Device Safety Action Plan for the next several months, with the goal that FDA "is consistently first among the world’s regulatory agencies to identify and act upon safety signals related to medical devices.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel